报价延迟最少15分钟:2026/03/09 09:20 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.09/-0.22
|
|
企业价值
2.08B
|
| 资产负债 |
|
每股账面净值
1.70
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
263.50M
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World. |
